# Indications for systemic fluoroquinolone prescribing in Europe: a descriptive population based study

First published: 06/09/2017

**Last updated:** 02/07/2024





## Administrative details

EU PAS number
EUPAS20889
Study ID
25386
DARWIN EU® study
No
Study countries
France
Germany
United Kingdom

#### Study description

A descriptive analysis of indications for treatment with systemic fluoroquinolone antibiotics in Summary of Product Characteristics across the European Economic Area (EEA) will first be conducted. Secondly a descriptive analysis of clinical indications for treatment with systemic fluoroquinolone antibiotics in France, Germany and UK will be conducted using electronic health records. Time trends in fluoroquinolone antibiotic use will be evaluated. Indications for acute sinusitis, acute bronchitis and uncomplicated urinary tract infection will specifically be evaluated.

#### **Study status**

**Finalised** 

#### Research institutions and networks

#### **Institutions**

## European Medicines Agency (EMA)

First published: 01/02/2024

**Last updated:** 01/02/2024

Institution

## Contact details

#### **Study institution contact**

Daniel Morales Daniel.Morales@ext.ema.europa.eu



Daniel.Morales@ext.ema.europa.eu

#### **Primary lead investigator**

#### **Daniel Morales**

**Primary lead investigator** 

## Study timelines

#### Date when funding contract was signed

Planned: 10/10/2016

Actual: 10/10/2016

#### **Study start date**

Planned: 17/10/2016

Actual: 17/10/2016

#### Data analysis start date

Planned: 14/11/2016

Actual: 14/11/2016

#### **Date of final study report**

Planned: 13/11/2017

Actual: 06/08/2018

## Sources of funding

EMA

## Study protocol

EUPAS20889.protocol.pdf (60 KB)

## Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

# Methodological aspects

## Study type

## Study type list

#### **Study topic:**

Disease /health condition

Human medicinal product

#### **Study type:**

Non-interventional study

#### Scope of the study:

Drug utilisation

#### **Data collection methods:**

Secondary use of data

#### Main study objective:

To provide a descriptive analysis of broad indications for treatment with systemic fluoroquinolone antibiotics in Summary of Product Characteristics across the European Economic Area (EEA). To provide a descriptive analysis of clinical indications for treatment with systemic fluoroquinolone antibiotics in France, Germany and UK electronic health records

## Study Design

#### Non-interventional study design

Other

#### Non-interventional study design, other

Descriptive analysis

## Study drug and medical condition

#### **Anatomical Therapeutic Chemical (ATC) code**

(J01MA) Fluoroquinolones

Fluoroquinolones

#### Medical condition to be studied

**Sinusitis** 

Bronchitis

Urinary tract infection

## Population studied

#### Short description of the study population

Patients were included from the IMS® Disease Analyzer France and Germany with a minimum period of 1 year follow-up defined according to their consultation and prescribing observability.

#### Age groups

- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)</li>
- Adults (75 to < 85 years)
- Adults (85 years and over)

#### Special population of interest

Other

#### Special population of interest, other

Sinusitis, Bronchitis, Urinary tract infection patients

#### **Estimated number of subjects**

200000

## Study design details

#### **Outcomes**

1) Descriptive analysis of the proportion of Summary of Product Characteristics across Europe with an indication for treatment for different indication categories. 2) Broad clinical indications for incident fluoroquinolone antibiotic prescribing in primary care.

#### Data analysis plan

The Summary of Product Characteristics for fluoroquinolone containing antibiotic products will be screened to identify what proportion have an indication listed for sinusitis, bronchitis and urinary tract infection. Incident fluoroquinolone prescriptions will be identified for adults in each electronic health record database. Read and ICD codes will be screened to identify the likely clinical indication for such recording. These will be broadly categorised according to different systems and specific information provided for sinusitis, bronchitis and urinary tract infection cross-sectionally. Time trends in the use of incident fluoroquinolone antibiotics will be provided for different broad system categories including for sinusitis, bronchitis and urinary tract infection for each database were data is available.

#### **Documents**

#### **Study results**

Summary.results.pdf (120.24 KB)

#### Study publications

Morales DR, Slattery J, Pinheiro L, Kurz X, Hedenmalm K. Indications for Systemi...

## Data management

## **ENCePP Seal**

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency

#### Data sources

#### Data source(s)

THIN® (The Health Improvement Network®)

**IQVIA** Disease Analyzer Germany

Disease Analyzer - OMOP

#### **Data sources (types)**

Electronic healthcare records (EHR)

## Use of a Common Data Model (CDM)

#### **CDM** mapping

No

## Data quality specifications

#### **Check conformance**

Unknown

#### **Check completeness**

Unknown

#### **Check stability**

Unknown

#### **Check logical consistency**

# Data characterisation

#### **Data characterisation conducted**

Unknown